A newly developed antibiotic called EVG7 could offer a powerful new way to stop Clostridioides difficile, a dangerous gut bacterium that often returns after treatment. In mouse studies, researchers ...

BOULDER, Colo.--(BUSINESS WIRE)--Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2 clinical trial evaluating CRS3123 in patients with Clostridioides difficile ...

As Clostridium difficile creates a significant economic and morbidity burden for hospitals, researchers with Cleveland Clinic and the University of Texas School of Public Health in Houston sought to ...

The U.S. Food and Drug Administration (FDA) has approved VOWST, a microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibacterial treatment for ...

Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical Trials Acurx is launching a ground-breaking clinical trial ...

Christian John Lillis, cofounder and executive director of the Peggy Lillis Foundation for C difficile Education & Advocacy, explained how FDA-approved microbiome-based therapeutics help to treat and ...

The Food and Drug Administration has approved a fecal microbiota pill to treat recurrent infections caused by Clostridium difficile (C. diff), an antibiotic-resistant bacterium deemed an urgent threat ...

Current guidelines recommend using either metronidazole or vancomycin to treat C. diff infections. “For many years the two antibiotics were considered to be equivalent in their ability to cure C. diff ...

The panelist discusses how recurrent Clostridioides difficile infections are frequently associated with complex comorbidities including inflammatory conditions, immunocompromise, gastrointestinal ...

Fecal microbiota transplantation has become one of the most effective treatments for recurrent Clostridioides difficile infections, but its long-term role in gastroenterology may hinge on moving ...

Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...

Crestone, Inc. ("Crestone") today announced recent publication in the leading infectious disease journal, The Lancet Infectious Diseases, of positive results from a Phase 2 clinical trial evaluating ...